Careers  |  Sign In  |  Register  |   Twitter

Poor Sales of Qsymia May Reflect Social Attitudes

An article in The New York Times reports on the sales difficulties facing Qsymia — the first new prescription weight loss drug to hit the U.S. market in 13 years — and how these struggles reflect a wider shift in attitude about dieting and exercise. The pill, manufactured by Vivus, only sold $4.1 million in the first quarter of this year despite $45 million in marketing, sales and administrative costs. Societal factors are partially to blame for the poor drug sales, including “the troubled history of diet drugs, and a feeling on the part of many doctors and obese people themselves that excess weight is a lifestyle issue best addressed by more willpower, rather than a disease that requires medical treatment.” Still, there may be a reversal of this trend since the American Medical Association declared in June that obesity is a disease.

Read it in The New York Times.